These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16054932)

  • 1. Effect of rimonabant on weight reduction and cardiovascular risk.
    Astrup A
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of rimonabant on weight reduction and cardiovascular risk.
    Esposito K; Giugliano D
    Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rimonabant on weight reduction and cardiovascular risk.
    van Oosten B; Killestein J; Polman Ch
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
    [No Abstract]   [Full Text] [Related]  

  • 10. Rimonabant in obese patients with type 2 diabetes.
    Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
    Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of rimonabant on weight reduction and cardiovascular risk.
    Hirschel B
    Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
    [No Abstract]   [Full Text] [Related]  

  • 12. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 13. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 15. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on rimonabant--a selective cannabinoid CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915
    [No Abstract]   [Full Text] [Related]  

  • 19. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.